



Society of
Actuaries®

Health^{'26} Meeting



Health^{'26} Meeting



ASOP No. 56—Modeling Meets Medicaid Risk Adjustment in New Academy Practice Note

July 23, 2026

Moderator:

David A. Quinn, MAAA, FSA

Presenters:

Nikhail Bharwani, MAAA, FSA

Jill A. Bruckert, MAAA, FSA

Julia Lerche, MAAA, FSA, MSPH

SOA Antitrust Compliance Guidelines

Active participation in the Society of Actuaries is an important aspect of membership. While the positive contributions of professional societies and associations are well-recognized and encouraged, association activities are vulnerable to close antitrust scrutiny. By their very nature, associations bring together industry competitors and other market participants.

The United States antitrust laws aim to protect consumers by preserving the free economy and prohibiting anti-competitive business practices; they promote competition. There are both state and federal antitrust laws, although state antitrust laws closely follow federal law. The Sherman Act, is the primary U.S. antitrust law pertaining to association activities. The Sherman Act prohibits every contract, combination or conspiracy that places an unreasonable restraint on trade. There are, however, some activities that are illegal under all circumstances, such as price fixing, market allocation and collusive bidding.

There is no safe harbor under the antitrust law for professional association activities. Therefore, association meeting participants should refrain from discussing any activity that could potentially be construed as having an anti-competitive effect. Discussions relating to product or service pricing, market allocations, membership restrictions, product standardization or other conditions on trade could arguably be perceived as a restraint on trade and may expose the SOA and its members to antitrust enforcement procedures.

While participating in all SOA in person meetings, webinars, teleconferences or side discussions, you should avoid discussing competitively sensitive information with competitors and follow these guidelines:

- **Do not** discuss prices for services or products or anything else that might affect prices
- **Do not** discuss what you or other entities plan to do in a particular geographic or product markets or with particular customers.
- **Do not** speak on behalf of the SOA or any of its committees unless specifically authorized to do so.
- **Do** leave a meeting where any anticompetitive pricing or market allocation discussion occurs.
- **Do** alert SOA staff and/or legal counsel to any concerning discussions
- **Do** consult with legal counsel before raising any matter or making a statement that may involve competitively sensitive information.

Adherence to these guidelines involves not only avoidance of antitrust violations, but avoidance of behavior which might be so construed. These guidelines only provide an overview of prohibited activities. SOA legal counsel reviews meeting agenda and materials as deemed appropriate and any discussion that departs from the formal agenda should be scrutinized carefully. Antitrust compliance is everyone's responsibility; however, please seek legal counsel if you have any questions or concerns.

Presentation Disclaimer

Presentations are intended for educational purposes only and do not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually and, unless expressly stated to the contrary, are not the opinion or position of the Society of Actuaries, its cosponsors or its committees. The Society of Actuaries does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented. Attendees should note that the sessions are audio-recorded and may be published in various media, including print, audio and video formats without further notice.

All numbers and charts are mock data and for illustrative purposes only.

About the Academy

5



Mission:

To serve the public and the U.S. actuarial profession



Community:

Serving over 20K MAAs & public stakeholders for 60 years



Standards:

Setting qualification, practice, and professionalism standards



Impact:

Delivering over 300 insight-driven publications & resources annually

Visit www.actuary.org to learn more.



Housekeeping

- Polling questions
- Q&A at the end of the session, time permitting

What Are Practice Notes?

- Examples of current and emerging approaches
- Non-binding
 - Often overlap with Actuarial Standards of Practice (ASOPs)

Risk Adjustment Practice Note Summary

- Medicaid (excluding long-term services and supports)
- Groupers versus component-weighted regression
- Concurrent versus prospective weights
- Medicaid program design and data interaction
- Data credibility
- Risk weight modeling and diagnostics

Risk Adjustment Primer

- Risk adjustment predicts expected cost from health status
 - Pay for acuity to control for selection bias
- Costs are usually in relative terms (1.0000 is average cost)
- Costs modeled by additive diagnoses or single grouper

Our Panelists



Nikhail Bharwani,
MAAA, FSA
Director, Actuarial
Centene Corporation




Jill A. Bruckert, MAAA,
FSA
Principal Actuary
Milliman



Julia Lerche, MAAA,
FSA, MSPH
Managing Director
Bailit Health

Question No. 1: Monotonically Increasing Cost Weights



For models with disease hierarchy weights, **how do you view a cost weight pattern with non-monotonically increasing weights?**

- *For example, Pulmonary regression coefficients:*
 - *Low* 0.5
 - *Medium* 2.9
 - *High* 2.6

Poll No. 1 (Q1): How Would You Handle Non-monotonically Increasing Weights?

- A. Use the weights as they are
- B. Retrain: Keep both coefficients constrained to equal/increasing weights
- C. Retrain: Combine the severities into one coefficient
- D. Retrain: Posterior weights with external data (i.e., Bayesian priors)
- E. Other

Question No. 2: Non-benefit Components

- Should any or all of the non-benefit component of a Medicaid capitation rate be risk-adjusted?



Benefits component of the rate

Non-Benefit Components:
Administrative,
Underwriting Margin,
Taxes, etc.

Question No. 3: Rate Cells

- Risk adjustment and rate cell stratification are partial substitutes as both aim to match payments to expected costs. **If the risk-adjustment model is predicting well, how do you decide how many rate cells to maintain?**

Question No. 4: Little Data

- Sometimes a beneficiary has few experience months. **What are ways to handle this issue?**

Poll No. 2 (Q4): How Would You Score a Beneficiary with Little Data?

- A. Exclude them
- B. Score them the average of all other scored beneficiaries
- C. Score them on subtotal average (e.g., geo./demo., managed care plan)
- D. Score them with a blend of group average and experience (credibility blending)

Question No. 5: Newer AI Methods

- Generative AI models have been used to review electronic medical records or claims to recommend *diagnosis codes* given doctor notes or procedure codes. **Which stakeholders are financially benefitting from this type of generative AI use?**

Poll No. 3 (Q5): Currently, Which Stakeholder Financially Benefits the Most from Generative AI Use?

- A. Beneficiaries
- B. Healthcare providers
- C. Electronic health record companies
- D. Insurers
- E. State Medicaid agencies
- F. Companies selling AI services
- G. All of the above
- H. None of the above
- I. Feels like an SOA multiple choice exam

Q&A

- Enforcing monotonicity
- Portion of capitation to adjust
- Rate cell level-of-detail
- Credibility and unscored beneficiaries
- Generative AI and diagnosis coding
- Other!

For more information, please contact

Michelle Anaba

Policy Project Manager, Health

anaba@actuary.org

Questions?



Provide Your Feedback

Health²⁶
Meeting